

Keith A A Fox

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2461631/keith-a-a-fox-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232 papers	47,376 citations	80 h-index	217 g-index
247 ext. papers	54,891 ext. citations	10.9 avg, IF	6.61 L-index

#	Paper	IF	Citations
232	Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 883-91	59.2	6302
231	Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet, The</i> , 2001 , 358, 527-33	40	2571
230	Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2006 , 354, 1706-17	59.2	2120
229	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. <i>European Heart Journal</i> , 2008 , 29, 2909-45	9.5	1774
228	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007 , 28, 1598-660	9.5	1438
227	Predictors of hospital mortality in the global registry of acute coronary events. <i>Archives of Internal Medicine</i> , 2003 , 163, 2345-53		1414
226	Rivaroxaban in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 366, 9-19	59.2	1357
225	A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. <i>New England Journal of Medicine</i> , 1997 , 337, 447-52	59.2	1192
224	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
223	A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 2727-33	27.4	1064
222	Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. <i>Circulation</i> , 2006 , 114, 774-82	16.7	1020
221	Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. <i>European Heart Journal</i> , 2003 , 24, 28-66	9.5	946
220	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). <i>BMJ, The</i> , 2006 , 333, 1091	5.9	941
219	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 354, 1464-76	59.2	922
218	Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). <i>Circulation</i> , 1998 , 98, 1510-6	16.7	919
217	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019 , 40, 237-269	9.5	851
216	Vorapaxar in the secondary prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2012 , 366, 1404-13	59.2	694

215	Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1519-30	27.4	685
214	Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. <i>Circulation</i> , 2004 , 110, 1202-8	16.7	667
213	Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1982-8	15.1	638
212	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
211	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010 , 376, 1233-43	40	624
210	Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1892-900	27.4	624
209	Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2010 , 363, 930-42	59.2	582
208	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2002 , 23, 1809-40	9.5	580
207	Early versus delayed invasive intervention in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 360, 2165-75	59.2	578
206	Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>Circulation</i> , 2003 , 108, 1682-7	16.7	578
205	Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 2908-17	27.4	534
204	International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. <i>Circulation</i> , 2007 , 116, 1942-51	16.7	487
203	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. <i>European Heart Journal</i> , 2011 , 32, 2387-94	9.5	440
202	Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). <i>American Journal of Cardiology</i> , 2002 , 90, 358-63	3	435
201	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. <i>New England Journal of Medicine</i> , 2010 , 363, 1704-14	59.2	428
200	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
199	Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. <i>Circulation</i> , 2010 , 121, 750-8	16.7	412
198	Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2435-45	15.1	403

197	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. <i>Circulation</i> , 2009 , 119, 2877-85	16.7	371
196	Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial Fibrillation) studies. <i>Stroke</i> , 2011 , 42, 133-141	16.7	359
195	Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). <i>European Heart Journal</i> , 2010 , 31, 2755-64	9.5	306
194	Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2011 , 123, 133-141	16.7	281
193	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011 , 32, 1854-64	9.5	273
192	High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. <i>BMJ, The</i> , 2015 , 350, g7873	5.9	256
191	Early and late effects of clopidogrel in patients with acute coronary syndromes. <i>Circulation</i> , 2003 , 107, 966-72	16.7	250
190	Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1998-2006	15.1	212
189	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	4.0	204
188	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1742-51	15.1	203
187	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , 2008 , 29, 609-17	9.5	195
186	Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. <i>Circulation</i> , 2007 , 116, 2793-801	16.7	182
185	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019 , 157, 682-691.e2	13.3	181
184	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1785-94	27.4	176
183	Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. <i>Circulation</i> , 2008 , 118, 1705-12	16.7	174
182	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2306-2315	15.1	173
181	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>Circulation</i> , 2010 , 121, 2575-83	16.7	173
180	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003 , 24, 1414-24	9.5	173

179	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 891-900	15.1	172
178	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016 , 37, 2882-2889	9.5	167
177	Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. <i>BMJ Open</i> , 2014 , 4, e004425	3	163
176	Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1471-8	15.1	159
175	Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. <i>Stroke</i> , 2014 , 45, 1304-12	6.7	151
174	The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009 , 158, 193-201.e1-5	4.9	145
173	High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. <i>Lancet, The</i> , 2018 , 392, 919-928	4.0	144
172	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1591-9	27.4	144
171	Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. <i>Annals of Internal Medicine</i> , 2004 , 140, 857-66	8	139
170	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). <i>American Journal of Cardiology</i> , 2004 , 93, 288-93	3	138
169	Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 693-8	15.1	130
168	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129
167	βBlockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2710-2720	15.1	127
166	Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. <i>Circulation: Cardiovascular Imaging</i> , 2012 , 5, 559-65	3.9	127
165	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2009 , 30, 655-61	9.5	121
164	Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. <i>American Heart Journal</i> , 2008 , 156, 1080-1088.e1	4.9	117
163	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2010 , 160, 16-22.e1	4.9	109
162	Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. <i>Stroke</i> , 2014 , 45, 1739-47	6.7	106

161	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017 , 194, 132-140	4.9	104
160	Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. <i>Circulation</i> , 2013 , 128, 823-33	16.7	103
159	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. <i>European Heart Journal</i> , 2009 , 30, 900-7	9.5	102
158	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035	3.8	97
157	Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. <i>Circulation</i> , 2005 , 111, 1390-7	16.7	96
156	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. <i>Circulation</i> , 2016 , 134, 37-47	16.7	93
155	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. <i>BMJ, The</i> , 2005 , 331, 869	5.9	87
154	Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials. <i>Heart</i> , 2012 , 98, 207-13	5.1	83
153	The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2249-55	15.1	80
152	Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR). <i>Circulation</i> , 2012 , 125, 568-76	16.7	75
151	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72
150	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017 , 135, 323-333	16.7	72
149	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). <i>American Heart Journal</i> , 2005 , 149, 217-26	4.9	71
148	Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. <i>Annals of Internal Medicine</i> , 2007 , 147, 304-10	8	70
147	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 34-59	4.3	69
146	An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 106-11	15.1	69
145	Thyroid disease and increased cardiovascular risk. <i>Thyroid</i> , 2005 , 15, 718-24	6.2	69
144	An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 1242-1248	7	67

143	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010 , 31, 50-8	9.5	64
142	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019 , 157, 403-412.e5	13.3	62
141	Blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 872-81	5.8	62
140	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>American Heart Journal</i> , 2005 , 150, 1177-84	4.9	61
139	High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2020 , 141, 161-171	16.7	61
138	Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2009 , 157, 1097-105	4.9	60
137	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015 , 128, 766-75	2.4	58
136	Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2015 , 4, e001956	6	58
135	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017 , 7, e017157	3	58
134	Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. <i>European Heart Journal</i> , 2011 , 32, 706-11	9.5	58
133	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018 , 39, 750-757a	9.5	56
132	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3271-3280	15.1	56
131	Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register. <i>European Heart Journal</i> , 2017 , 38, 974-982	9.5	55
130	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018 , 13, e0191592	3.7	53
129	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. <i>European Heart Journal</i> , 2010 , 31, 667-75	9.5	53
128	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 580-9		51
127	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019 , 140, 529-537	16.7	50
126	A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors. <i>European Journal of Heart Failure</i> , 2003 , 5, 489-97	12.3	48

125	Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. <i>PLoS Medicine</i> , 2018 , 15, e1002501	11.6	47
124	A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. <i>European Heart Journal</i> , 2010 , 31, 1132-41	9.5	46
123	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 121-130	15.1	46
122	Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2002 , 90, 477-82	3	45
121	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , 2018 , 39, 3798-3806	9.5	42
120	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 242-257	14.8	41
119	10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 511-20	15.1	40
118	Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. <i>Annals of Internal Medicine</i> , 2013 , 158, 861-8	8	39
117	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. <i>European Heart Journal</i> , 2010 , 31, 1328-36	9.5	39
116	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019 , 139, 787-798	16.7	39
115	The myth of 'stable' coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 9-21	14.8	39
114	Early diagnosis of acute coronary syndrome. <i>European Heart Journal</i> , 2017 , 38, 3049-3055	9.5	38
113	Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91,246 ambulant patients in 27 European countries. <i>European Heart Journal</i> , 2009 , 30, 3055-63	9.5	38
112	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. <i>Europace</i> , 2018 , 20, 1-11	3.9	35
111	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. <i>American Heart Journal</i> , 2008 , 155, 910-7	4.9	35
110	Performance of the GRACE Risk Score 2.0 Simplified Algorithm for Predicting 1-Year Death After Hospitalization for an Acute Coronary Syndrome in a Contemporary Multiracial Cohort. <i>American Journal of Cardiology</i> , 2016 , 118, 1105-1110	3	34
109	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 936-947	15.1	32
108	Rivaroxaban, an oral direct factor Xa inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 925-37	5.9	32

107	Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. <i>European Heart Journal</i> , 2013 , 34, 993-1001	9.5	31
106	Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). <i>European Heart Journal</i> , 2004 , 25, 2013-8	9.5	31
105	End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013 , 6, 470-8	5.8	30
104	The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. <i>Circulation</i> , 2020 , 142, 40-48	16.7	29
103	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome trial. <i>American Heart Journal</i> , 2015 , 169, 622-630.e6	4.9	27
102	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017 , 103, 1168-1176	5.1	25
101	Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). <i>American Journal of Cardiology</i> , 2012 , 109, 19-25	3	25
100	Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. <i>Annals of Surgery</i> , 2010 , 252, 37-42	7.8	25
99	Management of acute coronary syndromes: an update. <i>British Heart Journal</i> , 2004 , 90, 698-706		25
98	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2243-2250	15.1	24
97	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
96	Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. <i>American Heart Journal</i> , 2013 , 165, 123-32	4.9	24
95	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 114-122	4.6	23
94	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. <i>American Heart Journal</i> , 2009 , 157, 502-8	4.9	22
93	A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 708-14		22
92	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020 , 141, 1141-1151	16.7	21
91	Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 250-6		21
90	Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011 , 162, 347-355.e1	4.9	20

89	Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. <i>Stroke</i> , 2010 , 41, 1679-83	6.7	20
88	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2010 , 160, 855-61	4.9	20
87	An international perspective on acute coronary syndrome care: insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2004 , 148, S40-5	4.9	20
86	Assessment of Quality Indicators for Acute Myocardial Infarction in the FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	19
85	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. <i>Circulation</i> , 2017 , 135, 1001-1003	16.7	18
84	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , 2015 , 170, 995-1004.e1	4.9	18
83	Noninvasive, medical management for non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 155, 397-407	4.9	18
82	Registries and surveys in acute coronary syndrome. <i>European Heart Journal</i> , 2006 , 27, 2260-2	9.5	18
81	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
80	Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3	5	16
79	Clopidogrel: an updated and comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 621-631	5.5	16
78	Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TALISMAN) study. <i>European Heart Journal</i> , 2015 , 36, 625-635	4.9	15
77	Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction. <i>European Heart Journal</i> , 2021 , 42, 2552-2561	9.5	15
76	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 301-309	6.4	15
75	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 224-233	4.3	15
74	Association between time of hospitalization with acute myocardial infarction and in-hospital mortality. <i>European Heart Journal</i> , 2019 , 40, 1214-1221	9.5	14
73	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002471	5.2	14
72	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021 , 143, 2129-2142	16.7	14

71	High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. <i>Circulation</i> , 2021 , 143, 2214-2224	16.7	14
70	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002470	5.2	13
69	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1289-97	15.1	13
68	Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2014 , 168, 522-9	4.9	13
67	Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). <i>American Journal of Cardiology</i> , 2012 , 109, 6-12	3	13
66	Use of heparins in Non-ST-elevation acute coronary syndromes. <i>American Journal of Medicine</i> , 2007 , 120, 63-71	2.4	13
65	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. <i>Catheterization and Cardiovascular Interventions</i> , 2005 , 66, 149-57	2.7	13
64	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 21-29	16.2	12
63	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019 , 9, e032165	3	12
62	Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2020 , 3, e200107	10.4	11
61	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 304-313	16.2	11
60	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <i>International Journal of Cardiology</i> , 2019 , 278, 7-13	3.2	11
59	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017 , 244, 24-29	3.2	10
58	Dual or single antiplatelet therapy with anticoagulation?. <i>Lancet, The</i> , 2013 , 381, 1080-1	4.0	10
57	Effect of implementing routine early invasive strategy on one-year mortality in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2010 , 105, 36-42	3	10
56	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , 2016 , 102, 1396-402	5.1	10
55	Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 711-5	3.8	9
54	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 14-23	15.1	9

53	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. <i>Lancet, The</i> , 2022 , 399, 1383-1390	4.0	9
52	International comparison of acute myocardial infarction care and outcomes using quality indicators. <i>Heart</i> , 2019 , 105, 820-825	5.1	8
51	GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. <i>BMJ Open</i> , 2019 , 9, e033283	3	8
50	Have we reached the limit with thrombolytic therapy?. <i>Cardiovascular Drugs and Therapy</i> , 1999 , 13, 211-6.	3.9	8
49	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021 , 5, 1081-1091	7.8	8
48	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 27-35	4.6	8
47	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 309-317	4.6	7
46	Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries. <i>Europace</i> , 2020 , 22, 1635-1644	3.9	7
45	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021 , 117, 942-949	9.9	7
44	Frailty assessment and risk prediction by GRACE score in older patients with acute myocardial infarction. <i>BMC Geriatrics</i> , 2020 , 20, 102	4.1	5
43	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1332-1339	3.8	5
42	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 280-91	4.3	5
41	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
40	Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. <i>American Heart Journal</i> , 2020 , 222, 166-173	4.9	5
39	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
38	Comparative effectiveness of oral anticoagulants in everyday practice. <i>Heart</i> , 2021 ,	5.1	5
37	Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE). <i>Heart Lung and Circulation</i> , 2008 , 17, 5-8	1.8	4
36	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 309-317	4.3	4

35	Use of the GRACE score by cardiology nurse specialists in the emergency department. <i>British Journal of Cardiac Nursing</i> , 2010 , 5, 91-95	0.2	3
34	Long-term management of atherothrombosis. <i>British Journal of Hospital Medicine</i> , 2004 , 65, 206-9		3
33	A nationwide causal mediation analysis of survival following ST-elevation myocardial infarction. <i>Heart</i> , 2020 , 106, 765-771	5.1	3
32	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 511-525	15.1	3
31	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1322-1329	3	2
30	Acute coronary syndromes in 2010: progress from trials to practice. <i>Nature Reviews Cardiology</i> , 2011 , 8, 68-70	14.8	2
29	Clopidogrel in acute coronary heart disease. <i>The American Heart Hospital Journal</i> , 2005 , 3, 234-42		2
28	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006582	5.8	2
27	Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2322-2334	15.4	2
26	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021 ,	5.1	2
25	Anticoagulation in atrial fibrillation: the present and the future. <i>JRSM Cardiovascular Disease</i> , 2012 , 1,	1.1	1
24	In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The global registry of acute coronary events. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009 , 62, 501-9	0.7	1
23	Evoluci3n hospitalaria asociada al empleo de fibrinol3ticos y tienopiridinas en pacientes con infarto agudo de miocardio y elevaci3n del segmento ST. The Global Registry of Acute Coronary Events. <i>Revista Espanola De Cardiologia</i> , 2009 , 62, 501-509	1.5	1
22	Is clopidogrel plus aspirin more cost-effective than aspirin alone in high-risk patients with acute coronary syndromes?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 444-5		1
21	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 745-754	4.3	1
20	The 2020 ESC-ACVC quality indicators for the management of acute myocardial infarction applied to the FAST-MI registries. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 207-215	4.3	1
19	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , 2022 , 243, 147-157	4.9	1
18	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants 2013 , 332-397		1

17	Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry.. <i>BMJ Open</i> , 2022 , 12, e049933	3	o
16	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, E513-E522	2.7	o
15	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021 , 107, 1130-1137	5.1	o
14	Secondary prevention of MI: current approaches to treatment. <i>The Prescriber</i> , 2013 , 24, 23-29	0.4	
13	What's new for ESC Congress 2013? (Amsterdam 30th August-4th September 2013). <i>Egyptian Heart Journal</i> , 2013 , 65, 141-143	1.3	
12	What's new For ESC Congress 2013? (Amsterdam 30th August-4th September 2013). <i>Revista Portuguesa De Cardiologia</i> , 2013 , 32, 505-7	1	
11	Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy". <i>Circulation</i> , 2017 , 136, 117	16.7	
10	European Society of Cardiology Congress 2013 highlights. <i>Future Cardiology</i> , 2014 , 10, 23-6	1.3	
9	What's new for ESC congress 2013? (Amsterdam 30th august - 4th September 2013). <i>Acta Cardiologica</i> , 2013 , 68, 345-6	0.9	
8	NICE chest pain guidance. <i>Heart</i> , 2010 , 96, 1860-1860	5.1	
7	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).. <i>Heart and Vessels</i> , 2022 , 1	2.1	
6	Professor Keith AA Fox. <i>European Cardiology Review</i> , 2016 , 11, 60-61	3.9	
5	What's new for ESC Congress 2013? (Amsterdam 30th August-4th September 2013). <i>Archivos De Cardiologia De Mexico</i> , 2013 , 83, 232-3	0.2	
4	Reply: Do the 10-Year Mortality Outcomes of RITA-3 Inform Contemporary Clinical Practice?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1502-1503	15.1	
3	Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". <i>Circulation</i> , 2021 , 143, e3	16.7	
2	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021 , 331, 38-44	3.1	
1	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e022485	6	